What is PharmaCann?
PharmaCann, established in 2014 and headquartered in Chicago, IL, is dedicated to enhancing quality of life through the discovery, production, and responsible dispensing of cannabis-related products. The company aims to be a leader in the science-based understanding of cannabis's impact on healthcare and wellness industries. Its vision is rooted in scientific advancement and responsible market participation.
How much funding has PharmaCann raised?
PharmaCann has raised a total of $194.9M across 3 funding rounds:
Corporate Investment
$110.4M
Debt
$39.5M
Other Financing Round
$45M
Corporate Investment (2021): $110.4M with participation from The Cronos Group
Debt (2022): $39.5M, investors not publicly disclosed
Other Financing Round (2022): $45M supported by Innovative Industrial Properties
Key Investors in PharmaCann
The Cronos Group
The Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Founded in 2012 and headquartered in Toronto, Ontario, they focus on developing and distributing cannabinoid-based products.
Innovative Industrial Properties
Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on acquiring, owning, and managing specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
What's next for PharmaCann?
The recent major strategic investment signals PharmaCann's transition into a scaling phase, likely focusing on expanding its operational footprint, advancing its research and development initiatives, and potentially broadening its product portfolio. This infusion of capital will be critical for navigating the evolving regulatory landscape and solidifying its position as a key player in the science-driven cannabis market. Future endeavors will likely involve strategic partnerships and further market penetration.
See full PharmaCann company page
